Compare Novo Nordisk A/S (NVO) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Carparts.Com Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Carparts.Com Inc trades at $8.64 (market cap $66.42M). The key difference: Novo Nordisk A/S is far larger — about 2488.9× Carparts.Com Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Carparts.Com Inc for 45 Days on average.
| NVO | PRTS | |
|---|---|---|
Market Cap | $165.31B | $66.42M |
Volume | 11,432,838 | 40,287 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $10.00 |
52-Week Low | $35.29 | $3.88 |
Typical Hold Time | 116 Days | 45 Days |
Enterprise Value | $179.56B | $79.39M |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
CarParts.com (PRTS) trades at $8.59, down 1.21% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported a net loss of $50.44 million in 2025 despite beating earnings estimates in recent quarters. Revenue has declined from $676 million in 2023 to $548 million in 2025, though losses are projected to narrow in 2026. Analyst sentiment is positive with 60% buy ratings.
The outlook hinges on reversing revenue declines and achieving profitability. Investment opportunity lies in the low P/S ratio of 0.11 and potential for operational turnaround, but risks include persistent negative cash flow, competitive pressures, and execution challenges in a tough consumer discretionary market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
